Companies to Provide Advanced Oncology Imaging Solutions for the Clinical and Preclinical Domain
Munich and Berlin, Germany and Parsippany, New Jersey and Andover, Massachusetts – November 30, 2009 – Definiens, the number one Enterprise Image Intelligence® company, and Visage Imaging® Inc., a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME) announced today that they have entered into a partnership to jointly develop and market advanced oncology solutions for the clinical and preclinical imaging domain.
The partnership enables Definiens to utilize the Visage® CS enterprise visualization application in its forthcoming Definiens LymphExpert™ Version 2.0. By quantifying lymph nodes not only according to RECIST and WHO guidelines but also by their volume, the new integrated solution allows for efficient lesion analysis including automated quantification of lymph nodes. Visage’s technology provides Definiens LymphExpert™ Version 2.0 with a thin client based interface for full local and remote access as well as universal connectivity to image acquisition devices and image archives.
“Visage® CS provides an efficient workflow across different oncology applications. The platform’s intuitive user interface concept allowed us to seamlessly pair it with the Definiens LymphExpert™, resulting in an extremely fast and easy-to-use solution,” said Frank-P. Klein, Vice President, Medical Imaging at Definiens. “As a result, radiologists can now easily compare changes in lymph node size over time and thus derive additional information about the efficacy of a given therapy.”
“Definiens Lymph Expert allows for new levels of automation and efficiency in lymph node analysis. Adding this technology to the Visage platform is one important step in responding to the trend towards more quantitative and standardized diagnostics.” says Dr. Malte Westerhoff, CTO Visage Imaging.
“We are excited about this cooperation,” said David Chambers, CEO of Visage Imaging. “Definiens is one of the leading innovators in the area of image understanding and quantification. Their technology combined with our Thin Client based enterprise visualization platform will allow us to bring very attractive solutions to the clinical and pre-clinical imaging markets.”
